Infigratinib Phosphate API | FGFR Inhibitor Manufacturer & Supplier

Swapnroop Pharma · WHO-GMP Certified · +91 87670 62101

Infigratinib API

Infigratinib API is a synthetic small-molecule fibroblast growth factor receptor (FGFR) kinase inhibitor used in targeted oncology drug development. Infigratinib inhibits FGFR signaling, particularly FGFR1, FGFR2 and FGFR3, which are involved in cellular proliferation and tumor development.

The pharmaceutical form associated with the marketed product is Infigratinib Phosphate, also known as BGJ-398 phosphate. The phosphate salt has a molecular formula of C₂₆H₃₁Cl₂N₇O₃·H₃PO₄ and molecular weight of 658.47 g/mol.

Infigratinib was granted accelerated FDA approval in 2021 for previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with an FGFR2 fusion or rearrangement. However, the FDA states that this approval was withdrawn on May 16, 2024 following the sponsor's voluntary withdrawal request.

What is Infigratinib?

Infigratinib is an orally active targeted anticancer compound that inhibits FGFR tyrosine kinase activity. By blocking FGFR signaling, Infigratinib can interfere with signaling pathways involved in cancer-cell proliferation, survival and angiogenesis.

Infigratinib API Manufacturer & Supplier

Swapnroop Drugs and Pharmaceuticals provides Infigratinib API / Infigratinib Phosphate for qualified pharmaceutical manufacturing, formulation development and research requirements.

Infigratinib is a specialized oncology API relevant to FGFR-targeted drug development and pharmaceutical formulation applications.

Mechanism of Action

Infigratinib selectively inhibits the kinase activity of FGFR1, FGFR2 and FGFR3. Abnormal FGFR signaling caused by mutations, amplifications or gene fusions can contribute to uncontrolled cellular growth. Inhibiting this signaling pathway may reduce tumor-cell proliferation.

Pharmaceutical Applications

Infigratinib is associated with:

  • FGFR-targeted cancer research
  • FGFR2 fusion/rearrangement research
  • Cholangiocarcinoma drug development
  • Oncology formulation development
  • Targeted anticancer pharmaceutical research
  • FGFR inhibitor research

Detailed Specifications

Parameter Specification
Appearance White to off-white crystalline powder
Identification IR & HPLC compliant
Assay (HPLC) 98.0% – 102.0%
Loss on Drying NMT 1.0%
Residue on Ignition NMT 0.5%
Heavy Metals NMT 20 ppm
pH (1% Solution) 2.0 – 4.0
Individual Impurity NMT 0.5%
Total Impurities NMT 1.0%
Water Content NMT 1.0%
Melting Point 150°C – 154°C
Get Bulk Quote via WhatsApp